Zevra Therapeutics, Inc. - ZVRA

SEC FilingsOur ZVRA Tweets

About Gravity Analytica

Recent News

  • 09.08.2025 - H.C. Wainwright 27th Annual Global Investment Conference
  • 09.08.2025 - H.C. Wainwright 27th Annual Global Investment Conference
  • 09.04.2025 - Efficacy results across a 12-month double-blind randomized trial and an open-label extension phase of arimoclomol for treatment of Niemann-Pick disease type C in patients treated with miglustat
  • 09.04.2025 - Arimoclomol for the treatment of Niemann-Pick disease type C in a real-world setting: long-term outcomes from an expanded access program in the United States
  • 09.04.2025 - Arimoclomol upregulates expression of genes belonging to the coordinated lysosomal expression and regulation (CLEAR) network
  • 09.04.2025 - Safety and efficacy of arimoclomol in a pediatric substudy of Niemann-Pick disease type C patients aged 6 to
  • 09.04.2025 - Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)
  • 09.04.2025 - Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)
  • 09.03.2025 - Cantor Global Healthcare Conference
  • 09.03.2025 - Cantor Global Healthcare Conference

Recent Filings

  • 08.20.2025 - 4 Statement of changes in beneficial ownership of securities